January 8, 2013 Understanding Placebo Responses In Alzheimer’s Disease Clinical Trials From The Literature Meta-data And CAMD Database
U.S. Food and Drug Administration and European Medicines Agency Reach Landmark Decisions on Critical Path Institute’s Clinical Trial Simulation Tool for Alzheimer’s Disease
Development of a patient-reported outcome (PRO) instrument to assess complex activities of daily living and interpersonal functioning in patients with mild cognitive impairment due to suspected Alzheimer’s disease: the qualitative research phase
The advantages of frontotemporal degeneration drug development (Part 2 of frontotemporal degeneration: the next therapeutic frontier)
Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium
Understanding Placebo Responses in Alzheimer’s Disease Clinical Trials from the Literature Meta-Data and CAMD Database
C-Path Cosponsors Workshop on Combination Drug Development for Alzheimer’s Disease Combination therapy development has been successful in other life-threatening diseases in part because collaborative approaches we
